What factors drove the changes in Hims & Hers Health's revenue and profit?

What is Hims & Hers Health's latest dividend and current dividend yield?

Did Hims & Hers Health beat or miss consensus estimates last quarter?

What were the key takeaways from Hims & Hers Health’s earnings call?

What were the key takeaways from Hims & Hers Health's earnings call?

What is the market's earnings forecast for Hims & Hers Health next quarter?

What does Hims & Hers Health do and what are its main business segments?

What guidance did Hims & Hers Health's management provide for the next earnings period?

- **Record Growth**: Q3 2025 revenue surged 49% YoY to $600 million, driven by personalized solutions and new specialties like menopause and weight loss.
- **Strategic Expansion**: Launched lab testing and invested $1.1 billion in cash to accelerate international expansion (Canada, Europe) and verticalize compounding infrastructure.
- **Partnerships & Innovation**: Partnered with Novo Nordisk and GRAIL, reduced GLP-1 prices by 20%, and plans to launch longevity treatments in 2026.
- **Long-Term Vision**: On track to meet 2030 targets of $6.5 billion in revenue and $1.3 billion in EBITDA, despite near-term margin headwinds from investments.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue reached nearly $600 million, up 49% YoY, driven by personalized solutions and new specialties like weight loss and menopause care.
- **Strategic Initiatives**: Launched partnerships with Novo Nordisk (Wegovy) and GRAIL (multi-cancer early detection), and invested in verticalized compounding infrastructure to reduce costs and improve accessibility.
- **New Offerings**: Introduced low testosterone treatment, perimenopause/menopause support, and plans to launch comprehensive lab testing by year-end 2025. Microdosing options for compounded semaglutide were also added.
- **International Expansion**: Acquired Zava Global to enter U.K., Germany, France, Ireland, and Spain; preparing to launch in Canada in 2026.
- **Long-Term Vision**: Aims to become the largest global consumer health platform, with 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA.

**【CFO Financial Commentary】**
- **Profitability**: Adjusted EBITDA grew 50% YoY to $78 million, with margins above 13%. Marketing spend as a percentage of revenue declined 6pts YoY due to lower-cost channels and higher retention.
- **Gross Margin Pressure**: Declined 2pts QoQ to 74% due to shorter shipment cadences for weight loss products, but expects normalization in 2H 2026.
- **Cash Flow**: Generated $149 million in operating cash flow, with $1.1 billion in total cash and investments.
- **Investments**: Planning to expand operational footprint to over 1 million sq ft by year-end, and increase R&D in AI and diagnostics.

**【Q&A Highlights】**
- **Lab Testing & Longevity**: Launched whole-body lab testing before year-end, with a longevity specialty (peptides, GLP-1s) set to launch in 2026. Prices for compounded GLP-1s were reduced by 20% to expand accessibility.
- **Core Business Growth**: Despite near-term headwinds from sexual health transition, expects acceleration in 2H 2026 as daily solutions and multi-condition plans gain traction.
- **International Momentum**: Zava contributed $50 million+ in incremental revenue in Q3, with strong demand in Europe. Canada launch expected to capitalize on 2/3 of adults living with obesity.
- **Margin Outlook**: Anticipates temporary margin contraction in 2026 due to investments, but confident in long-term free cash flow generation.
- **Partnerships**: Actively negotiating with Novo Nordisk for Wegovy distribution, and exploring collaborations to bring advanced diagnostics and treatments to consumers.

Hims & Hers Health, Inc. (HIMS) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

HIMS

HIMS fundamentals

You can ask Aime